Skip to main content
Erschienen in: Rheumatology International 4/2008

01.02.2008 | Original Article

The −844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis

verfasst von: Nora Magdalena Torres-Carrillo, Norma Torres-Carrillo, Mónica Vázquez-Del Mercado, Vidal Delgado-Rizo, Edith Oregón-Romero, Isela Parra-Rojas, José Francisco Muñoz-Valle

Erschienen in: Rheumatology International | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

We assessed whether the −844 G/A polymorphism and mRNA expression of plasminogen activator inhibitor 1 (PAI-1) gene are associated with rheumatoid arthritis (RA). Demographic data, hematological, biochemical parameters, disease activity–disability indexes, −844 G/A genotypes and mRNA expression levels of the PAI-1 gene were determined in 50 RA patients and 50 healthy subjects (HS). Non-significant differences in genotype and allele frequencies related to −844 G/A polymorphism in RA versus HS, were found. High mRNA expression of the PAI-1 gene, was demonstrated in RA versus HS (P < 0.05). In addition, A/A genotype carriers showed increase of PAI-1 mRNA expression (3.1-fold) respect to G/G and G/A genotypes in RA patients (P < 0.05). Our finding suggest an association of A/A −844 PAI-1 genotype with high PAI-1 mRNA expression in RA patients.
Literatur
2.
Zurück zum Zitat Firestein GS (2005) Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11:S39–S44PubMedCrossRef Firestein GS (2005) Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11:S39–S44PubMedCrossRef
3.
Zurück zum Zitat Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:1–9CrossRef Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:1–9CrossRef
4.
Zurück zum Zitat Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res 45:101–106CrossRef Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res 45:101–106CrossRef
5.
Zurück zum Zitat Gils A, Declerck PJ (2004) Plasminogen activator inhibitor-1. Curr Med Chem 11:2323–2334PubMed Gils A, Declerck PJ (2004) Plasminogen activator inhibitor-1. Curr Med Chem 11:2323–2334PubMed
6.
Zurück zum Zitat Agirbasli M (2005) Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59:102–106PubMedCrossRef Agirbasli M (2005) Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59:102–106PubMedCrossRef
7.
Zurück zum Zitat Busso N, Péclat V, So A, Sappino AP (1997) Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56:550–557PubMedCrossRef Busso N, Péclat V, So A, Sappino AP (1997) Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56:550–557PubMedCrossRef
8.
Zurück zum Zitat Ruiz-Quezada S, Vázquez-Del Mercado M, Parra-Rojas I, Rangel-Villalobos H, Best-Aguilera C, Sánchez-Orozco LV, Muñoz-Valle JF (2004) Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet 47:155–162PubMed Ruiz-Quezada S, Vázquez-Del Mercado M, Parra-Rojas I, Rangel-Villalobos H, Best-Aguilera C, Sánchez-Orozco LV, Muñoz-Valle JF (2004) Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet 47:155–162PubMed
9.
Zurück zum Zitat Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR (1996) A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84:431–443PubMedCrossRef Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR (1996) A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84:431–443PubMedCrossRef
10.
Zurück zum Zitat Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I (1997) Five frequent polymorphisms of the PAI-1 gene lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17:851–858PubMed Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I (1997) Five frequent polymorphisms of the PAI-1 gene lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17:851–858PubMed
11.
Zurück zum Zitat Morange PE, Henry M, Tregouët D, Granel B, Aillaud MF, Alessi MC, Juhan-Vague I (2000) The A −844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20:1387–1391PubMed Morange PE, Henry M, Tregouët D, Granel B, Aillaud MF, Alessi MC, Juhan-Vague I (2000) The A −844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20:1387–1391PubMed
12.
Zurück zum Zitat Lopes C, Dina C, Durand E, Froguel P (2003) PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 46:1284–1290PubMedCrossRef Lopes C, Dina C, Durand E, Froguel P (2003) PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 46:1284–1290PubMedCrossRef
13.
Zurück zum Zitat Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I (1998) Metabolic determinations are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. A family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 18:84–91PubMed Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I (1998) Metabolic determinations are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. A family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 18:84–91PubMed
14.
Zurück zum Zitat Lu F, Hong J, Kening S, Cuili Z, Jingxia S, Yonglin H (2001) Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction. Chin Med J 114:266–269 Lu F, Hong J, Kening S, Cuili Z, Jingxia S, Yonglin H (2001) Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction. Chin Med J 114:266–269
15.
Zurück zum Zitat Haselbauer A, Haberbosch W, Tillmanns H, Gardemann A (2002) The impact of the PAI-1 A(−844)G promoter polymorphism on the risk and extent of coronary heart disease. Thromb Haemost 88:697–698PubMed Haselbauer A, Haberbosch W, Tillmanns H, Gardemann A (2002) The impact of the PAI-1 A(−844)G promoter polymorphism on the risk and extent of coronary heart disease. Thromb Haemost 88:697–698PubMed
16.
Zurück zum Zitat Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D (1993) How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 11:117–121PubMed Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D (1993) How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 11:117–121PubMed
17.
Zurück zum Zitat Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
18.
Zurück zum Zitat Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef
19.
Zurück zum Zitat Vázquez-Del Mercado M, Delgado-Rizo V, Muñoz-Valle JF, Orozco-Alcalá J, Volk HD, Armendáriz-Borunda J (1999) Expression of interleukin-1β, tumor necrosis factor α, interleukins−6, −10 and −4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid artritis patients. Clin Exp Rheumatol 17:575–583PubMed Vázquez-Del Mercado M, Delgado-Rizo V, Muñoz-Valle JF, Orozco-Alcalá J, Volk HD, Armendáriz-Borunda J (1999) Expression of interleukin-1β, tumor necrosis factor α, interleukins−6, −10 and −4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid artritis patients. Clin Exp Rheumatol 17:575–583PubMed
20.
Zurück zum Zitat Muñoz-Valle JF, Vázquez-Del Mercado M, García-Iglesias T, Orozco-Barocio G, Bernard-Medina G, Martínez-Bonilla G, Bastidas-Ramírez BE, Navarro AD, Bueno M, Martínez-López E, Best-Aguilera CR, Kamachi M, Armendáriz-Borunda J (2003) TH1/TH2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol 131:377–384PubMedCrossRef Muñoz-Valle JF, Vázquez-Del Mercado M, García-Iglesias T, Orozco-Barocio G, Bernard-Medina G, Martínez-Bonilla G, Bastidas-Ramírez BE, Navarro AD, Bueno M, Martínez-López E, Best-Aguilera CR, Kamachi M, Armendáriz-Borunda J (2003) TH1/TH2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol 131:377–384PubMedCrossRef
21.
Zurück zum Zitat Fabbro D, Délia AV, Spizzo R, Driul L, Barillari G, Di Loreto C, Marcheson D (2003) Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest 56:17–22PubMedCrossRef Fabbro D, Délia AV, Spizzo R, Driul L, Barillari G, Di Loreto C, Marcheson D (2003) Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest 56:17–22PubMedCrossRef
22.
Zurück zum Zitat Smolarz B, Blasiak J, Kulig A, Romanowicz-Makowska H, Ulanska J, Pander B, Szewczyk T (2001) Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res 20:247–252PubMed Smolarz B, Blasiak J, Kulig A, Romanowicz-Makowska H, Ulanska J, Pander B, Szewczyk T (2001) Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res 20:247–252PubMed
23.
Zurück zum Zitat Keene JD (2001) Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl Acad Sci USA 98:7018–7024PubMedCrossRef Keene JD (2001) Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl Acad Sci USA 98:7018–7024PubMedCrossRef
24.
Zurück zum Zitat Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef
25.
Zurück zum Zitat Svenson KLG, Lithell H, Hallgren R, Vessby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 147:1917–1920PubMedCrossRef Svenson KLG, Lithell H, Hallgren R, Vessby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 147:1917–1920PubMedCrossRef
26.
Zurück zum Zitat Wallace DJ (1994) Antimalarial agents and lupus. In systemic lupus erythematosus. Dis Clin North Am 20:243–263 Wallace DJ (1994) Antimalarial agents and lupus. In systemic lupus erythematosus. Dis Clin North Am 20:243–263
27.
Zurück zum Zitat Nodis HN, Quismorio FP, Wickham E, Blankenhorn DH (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxyl-chloroquine in patients with systemic lupus erythematosus. J Rheumatol 20:661–665 Nodis HN, Quismorio FP, Wickham E, Blankenhorn DH (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxyl-chloroquine in patients with systemic lupus erythematosus. J Rheumatol 20:661–665
Metadaten
Titel
The −844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis
verfasst von
Nora Magdalena Torres-Carrillo
Norma Torres-Carrillo
Mónica Vázquez-Del Mercado
Vidal Delgado-Rizo
Edith Oregón-Romero
Isela Parra-Rojas
José Francisco Muñoz-Valle
Publikationsdatum
01.02.2008
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 4/2008
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0453-z

Weitere Artikel der Ausgabe 4/2008

Rheumatology International 4/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.